CYP2C19
UK's NICE Recommends Genetic Testing for Therapy Selection in Stroke Patients
Clopidogrel is less effective at preventing subsequent strokes in patients with certain variations in the CYP2C19 gene and testing could aid treatment selection.
PGx-Guided Dosing Can Lead to Faster Therapeutic Blood Levels of Antidepressants
A randomized controlled trial compared cytochrome P450 genotype-based dosing of tricyclic antidepressants to usual care among patients with depression.
Genomadix Gets FDA 510(k) Clearance for PCR System, CYP2C19 Test
Canada's Genomadix, formerly known as Spartan Bioscience, expects to now commercialize the system and test in the US to guide therapy decisions.
In multiple presentations, researchers at ACC/WCC's annual meeting explored the impact of genotyping cardiac patients within a week of starting dual anti-platelet therapy.
As part of the program, point-of-care tests sold by Genedrive and Genomadix will be assessed, as well as laboratory-developed tests used within the UK National Health Service.